ScripWhile the concept of using natural killer cell-based therapies emerged more than a decade ago, no company has yet brought one to market, but Zelluna believes its unique T-Cell Receptor natural killer
ScripAfter a year littered with clinical failures for its cancer vaccine UV1, Ultimovacs has managed to secure survival by combining with fellow Norwegian biotech Zelluna Immunotherapy. The deal is structu
In VivoEstablished only last year and incorporated in France and Spain with an initial seed from Paris-based VC firm AdBio Partners, Kiji Therapeutics is grounded in science from the Spanish public research